候选疫苗-话题@MedSci

#候选疫苗#

43篇内容 | 1646人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1937319, encodeId=d614193e3198f, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=预防登革热枢纽性临床试验显示，武田的登革热候选疫苗可提供持续4.5年的保护力, objectType=article, longId=729130, objectId=308be2913085, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=308be2913085, replyNumber=0, likeNumber=108, createdTime=2023-03-22, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=308be2913085, moduleTitle=预防登革热枢纽性临床试验显示，武田的登革热候选疫苗可提供持续4.5年的保护力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=308be2913085)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937318, encodeId=03b9193e3185a, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=三叶草新冠候选疫苗作为加强针对奥密克戎的强烈免疫应答，且具有高且持久的保护效力, objectType=article, longId=723710, objectId=7b2ce23710ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b2ce23710ee, replyNumber=0, likeNumber=100, createdTime=2022-11-07, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b2ce23710ee, moduleTitle=三叶草新冠候选疫苗作为加强针对奥密克戎的强烈免疫应答，且具有高且持久的保护效力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b2ce23710ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937313, encodeId=036e193e313e5, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=防御南非变种！Moderna的变异特异性COVID-19候选疫苗即将进入临床阶段, objectType=article, longId=207592, objectId=d9be20e59233, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9be20e59233, replyNumber=0, likeNumber=81, createdTime=2022-01-03, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9be20e59233, moduleTitle=防御南非变种！Moderna的变异特异性COVID-19候选疫苗即将进入临床阶段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9be20e59233)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937315, encodeId=ad48193e31526, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=BMJ：英国开始两种候选疫苗都对老年人有效, objectType=article, longId=211349, objectId=95452113493b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95452113493b, replyNumber=0, likeNumber=65, createdTime=2021-08-29, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95452113493b, moduleTitle=BMJ：英国开始两种候选疫苗都对老年人有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95452113493b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937314, encodeId=24a2193e31408, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=柳叶刀：新冠肺炎候选疫苗Sputnik V似乎安全有效, objectType=article, longId=208798, objectId=d5f0208e98f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5f0208e98f4, replyNumber=0, likeNumber=85, createdTime=2021-07-15, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5f0208e98f4, moduleTitle=柳叶刀：新冠肺炎候选疫苗Sputnik V似乎安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5f0208e98f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937311, encodeId=1c72193e31124, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募, objectType=article, longId=206516, objectId=fdf420651685, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdf420651685, replyNumber=0, likeNumber=74, createdTime=2021-05-05, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdf420651685, moduleTitle=COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdf420651685)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937309, encodeId=5a5c193e309fe, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=Lancet子刊：COVID-19 DNA候选疫苗INO-4800的I期临床，在所有患者中触发免疫原性, objectType=article, longId=204904, objectId=620a20490483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=620a20490483, replyNumber=0, likeNumber=90, createdTime=2021-12-12, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=620a20490483, moduleTitle=Lancet子刊：COVID-19 DNA候选疫苗INO-4800的I期临床，在所有患者中触发免疫原性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=620a20490483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937317, encodeId=45dd193e31736, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=武田和Frazier Healthcare Partners宣布合作成立HilleVax, Inc.以开发临床阶段诺如病毒候选疫苗, objectType=article, longId=215179, objectId=45d52151e9f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45d52151e9f8, replyNumber=0, likeNumber=78, createdTime=2022-07-11, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45d52151e9f8, moduleTitle=武田和Frazier Healthcare Partners宣布合作成立HilleVax, Inc.以开发临床阶段诺如病毒候选疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45d52151e9f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937304, encodeId=789b193e3047e, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=NEJM：核苷修饰RNA候选疫苗BNT162b1，BNT162b2用于新冠肺炎的预防, objectType=article, longId=202160, objectId=6284202160c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6284202160c3, replyNumber=0, likeNumber=67, createdTime=2021-03-15, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6284202160c3, moduleTitle=NEJM：核苷修饰RNA候选疫苗BNT162b1，BNT162b2用于新冠肺炎的预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6284202160c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937306, encodeId=34a7193e3063a, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=新加坡COVID-19候选疫苗（ARCT-021）表现良好，或将于2021年第一季度交付使用, objectType=article, longId=203836, objectId=cae620383623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cae620383623, replyNumber=0, likeNumber=80, createdTime=2021-07-18, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cae620383623, moduleTitle=新加坡COVID-19候选疫苗（ARCT-021）表现良好，或将于2021年第一季度交付使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cae620383623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937316, encodeId=7d69193e316b1, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=长期安全性和有效性结果凸显武田登革热候选疫苗的潜在影响力, objectType=article, longId=211814, objectId=fe53211814ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe53211814ff, replyNumber=0, likeNumber=79, createdTime=2022-02-21, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe53211814ff, moduleTitle=长期安全性和有效性结果凸显武田登革热候选疫苗的潜在影响力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe53211814ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937312, encodeId=560c193e312f7, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=Lancet：SCB-2019，COVID-19的又一具有潜力的候选疫苗！, objectType=article, longId=206654, objectId=800a206654c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=800a206654c4, replyNumber=0, likeNumber=72, createdTime=2021-04-04, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=800a206654c4, moduleTitle=Lancet：SCB-2019，COVID-19的又一具有潜力的候选疫苗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=800a206654c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937310, encodeId=d022193e31045, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=低于辉瑞疫苗！美国第2款新冠候选疫苗mRNA-1273疗效公布, objectType=article, longId=205349, objectId=8e42205349da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e42205349da, replyNumber=0, likeNumber=60, createdTime=2021-06-07, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e42205349da, moduleTitle=低于辉瑞疫苗！美国第2款新冠候选疫苗mRNA-1273疗效公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e42205349da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937300, encodeId=83fb193e300a4, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=CDMO或可加速COVID-19候选疫苗的大规模生产, objectType=article, longId=198198, objectId=d29019819849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d29019819849, replyNumber=0, likeNumber=75, createdTime=2021-02-28, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d29019819849, moduleTitle=CDMO或可加速COVID-19候选疫苗的大规模生产, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d29019819849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937307, encodeId=6772193e307c4, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=三叶草生物发布“S-三聚体”重组亚单位新冠候选疫苗 I 期研究积极结果, objectType=article, longId=204282, objectId=07ac2042820a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07ac2042820a, replyNumber=0, likeNumber=77, createdTime=2021-11-17, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07ac2042820a, moduleTitle=三叶草生物发布“S-三聚体”重组亚单位新冠候选疫苗 I 期研究积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07ac2042820a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937301, encodeId=6e82193e30164, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=Nature新冠病毒研究进展盘点：候选疫苗保护猴子不受感染？, objectType=article, longId=198932, objectId=f3e219893294, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3e219893294, replyNumber=0, likeNumber=70, createdTime=2021-07-05, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3e219893294, moduleTitle=Nature新冠病毒研究进展盘点：候选疫苗保护猴子不受感染？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3e219893294)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937302, encodeId=7dbb193e3023d, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=COVID-19候选疫苗LUNAR®-COV19（ARCT-021）：临床前研究确认了有效性, objectType=article, longId=200319, objectId=d68c20031934, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d68c20031934, replyNumber=0, likeNumber=70, createdTime=2021-02-07, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d68c20031934, moduleTitle=COVID-19候选疫苗LUNAR®-COV19（ARCT-021）：临床前研究确认了有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d68c20031934)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937285, encodeId=2a40193e28578, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=英国COVID-19候选疫苗ChAdOx1：将于下个月开始临床试验, objectType=article, longId=190564, objectId=50ab190564bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50ab190564bf, replyNumber=0, likeNumber=77, createdTime=2021-03-03, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50ab190564bf, moduleTitle=英国COVID-19候选疫苗ChAdOx1：将于下个月开始临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50ab190564bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937303, encodeId=144e193e3036c, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验, objectType=article, longId=201324, objectId=3539201324d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3539201324d6, replyNumber=0, likeNumber=66, createdTime=2021-07-28, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3539201324d6, moduleTitle=Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3539201324d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937295, encodeId=5168193e29581, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=COVID-19候选疫苗SCB-2019进展顺利, objectType=article, longId=196290, objectId=1ce1196290e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ce1196290e4, replyNumber=0, likeNumber=53, createdTime=2021-01-12, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ce1196290e4, moduleTitle=COVID-19候选疫苗SCB-2019进展顺利, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ce1196290e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

候选疫苗

2020-05-29

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

预防登革热枢纽性临床试验显示，武田的登革热候选疫苗可提供持续4.5年的保护力

2023-03-22

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

三叶草新冠候选疫苗作为加强针对奥密克戎的强烈免疫应答，且具有高且持久的保护效力

2022-11-07

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

防御南非变种！Moderna的变异特异性COVID-19候选疫苗即将进入临床阶段

2022-01-03

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

BMJ：英国开始两种候选疫苗都对老年人有效

2021-08-29

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

柳叶刀：新冠肺炎候选疫苗Sputnik V似乎安全有效

2021-07-15

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

COVID-19候选疫苗VLA2001已完成I / II期临床试验的患者招募

2021-05-05

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

Lancet子刊：COVID-19 DNA候选疫苗INO-4800的I期临床，在所有患者中触发免疫原性

2021-12-12

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

武田和Frazier Healthcare Partners宣布合作成立HilleVax, Inc.以开发临床阶段诺如病毒候选疫苗

2022-07-11

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

NEJM：核苷修饰RNA候选疫苗BNT162b1，BNT162b2用于新冠肺炎的预防

2021-03-15

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

新加坡COVID-19候选疫苗（ARCT-021）表现良好，或将于2021年第一季度交付使用

2021-07-18

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

长期安全性和有效性结果凸显武田登革热候选疫苗的潜在影响力

2022-02-21

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

Lancet：SCB-2019，COVID-19的又一具有潜力的候选疫苗！

2021-04-04

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

低于辉瑞疫苗！美国第2款新冠候选疫苗mRNA-1273疗效公布

2021-06-07

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

CDMO或可加速COVID-19候选疫苗的大规模生产

2021-02-28

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

三叶草生物发布“S-三聚体”重组亚单位新冠候选疫苗 I 期研究积极结果

2021-11-17

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

Nature新冠病毒研究进展盘点：候选疫苗保护猴子不受感染？

2021-07-05

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

COVID-19候选疫苗LUNAR®-COV19（ARCT-021）：临床前研究确认了有效性

2021-02-07

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

英国COVID-19候选疫苗ChAdOx1：将于下个月开始临床试验

2021-03-03

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验

2021-07-28

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

COVID-19候选疫苗SCB-2019进展顺利

2021-01-12

科室
- - 订阅+
  - 更多科室
工具
服务